Glaucoma Drug's Flop Has OCUL Stock Spiraling

Several analysts, including Cowen and Raymond James hit the stock with downgrades

Digital Content Manager
May 21, 2019 at 9:37 AM
facebook twitter linkedin


Pharma stock Ocular Therapeutix Inc (NASDAQ:OCUL) is in hot water today, down 11% at $3.00 in early trading, and pacing for its worst day since Dec. 3. The stock is fresh off a new record low of $2.78, too, after the company's glaucoma treatment, OTX-TP, fell short of its main goal in a late-stage study.

A round of bear notes is doing the equity no favors. Cowen and Company downgraded OCUL to a "market perform" from "outperform," and slashed its target price by a whopping $10 dollars to $3 a share, while Raymond James cut its rating to "outperform" from "strong buy," and dropped its target price to $5 from $11. Wainwright joined suit, cutting its price target to $9 from $12.

Considering the stock's longer-term technical troubles, this analyst drubbing feels long overdue. OCUL stock has been trading in a channel of lower highs and lows since a late-February spike, pressured by its declining 100-day moving average. Plus, Ocular Therapeutics has lost 56% year-over-year. Nevertheless, four "strong buy" ratings were on the table at last night's close, while the consensus 12-month target price of $10.17 more than doubles the security's current price.

Shorts are likely celebrating the equity's bear gap today, as short interest shot up over 14% in the last two reporting periods. The 8.4 million shares sold short represents a whopping 28.9% of the stocks available float, or nearly three weeks of trading at OCUL's average pace. However, these traders are sidelined today, with the stock landing on the short-sale restricted list.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners